These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38002466)

  • 1. Cytokine Gene Vaccine Therapy for Treatment of a Brain Tumor.
    Lichtor T; Tang B; Roy EJ
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogene therapy as a treatment for malignant brain tumors in young mice.
    Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
    J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
    Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
    Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
    Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
    Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine immuno-gene therapy for treatment of brain tumors.
    Lichtor T; Glick RP
    J Neurooncol; 2003 Dec; 65(3):247-59. PubMed ID: 14682375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice.
    Deshmukh P; Glick RP; Lichtor T; Moser R; Cohen EP
    J Neurosurg; 2001 Feb; 94(2):287-92. PubMed ID: 11213967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
    Glick RP; Lichtor T; Panchal R; Mahendra A; Cohen EP
    J Neurooncol; 2003; 64(1-2):139-46. PubMed ID: 12952294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
    Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
    Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system.
    Griffitt W; Glick RP; Lichtor T; Cohen EP
    Neurosurgery; 1998 Feb; 42(2):335-40. PubMed ID: 9482184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine.
    Lichtor T; Glick RP; O-Sullivan I; Cohen EP
    Curr Genomics; 2006 Jun; 7(4):253-261. PubMed ID: 17160140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
    Lichtor T; Glick RP; Lin H; O-Sullivan I; Cohen EP
    Cancer Gene Ther; 2005 Aug; 12(8):708-14. PubMed ID: 15803143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
    Spagnolo A; Glick RP; Lin H; Cohen EP; Feinstein DL; Lichtor T
    J Neurosurg; 2007 Feb; 106(2):299-305. PubMed ID: 17410715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine immunogene therapy.
    Glick RP; Lichtor T; Cohen EP
    Neurosurg Focus; 2000 Dec; 9(6):e2. PubMed ID: 16817685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
    Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
    Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the use of cytokine gene-modified tumor cells in immunotherapy of cancer.
    Qin Z; Blankenstein T
    Methods Mol Med; 1997; 7():339-48. PubMed ID: 24493438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
    Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
    J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
    Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
    J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
    Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
    Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.